Estimation and application of biological variation of urinary δ-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria

Clinical Chemistry

Volumn 52, Issue 4, 2006, Pages 650-656

  Aarsand, Aasne K ^a,b   Petersen, Per Hyltoft ^b   Sandberg, Sverre ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; PORPHOBILINOGEN;

ACUTE INTERMITTENT PORPHYRIA; ADOLESCENT; ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PROBABILITY; REFERENCE VALUE; REMISSION; SCHOOL CHILD; STANDARD; SYMPTOM; URINALYSIS; URINE LEVEL; VARIANCE;

ADULT; AMINOLEVULINIC ACID; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PORPHOBILINOGEN; PORPHYRIA, ACUTE INTERMITTENT; PROBABILITY; REFERENCE VALUES;

EID: 33645456314     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.060772     Document Type: Article

References (26)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001:2961-3062.
2. Andersson C, Thunell S, Floderus Y, Forsell C, Lundin G, Anvret M, et al. Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. J Intern Med 1995;237:301-8.
3. European Porphyria Initiative (EPI). www.porphyria-europe.com (accessed December 2005).
4. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002;48:1891-900.
5. Kauppinen R. Porphyrias. Lancet 2005;365:241-52.
6. Harris EK. Effects of intra- and interindividual variation on the appropriate use of normal ranges. Clin Chem 1974;20:1535-42.
7. Sandberg S, Elder GH. Diagnosing acute porphyrias [Editorial]. Clin Chem 2004;50:803-5.
8. The Drug Database for Acute Porphyria. www.drugs-porphyria.org (accessed December 2005).
9. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
10. Neuilly M. CETAMA. Modelling and estimation of measurement errors. Paris: Intercept Ltd., 1999:54-5.
11. Kringle RO, Bogovich M. Statistical procedure. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: WB Saunders, 1999:265-309.
12. Biosca C, Ricos C, Jimenez CV, Lauzurica R, Galimany R. Model for establishing biological variation in non-healthy situations: renal posttransplantation data. Clin Chem 1997;43:2206-8.
13. Trape J, Botargues JM, Porta F, Ricos C, Badal JM, Salinas R, et al. Reference change value for α-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003;49:1209-11.
14. Holzel WG. Intra-individual variation of some analytes in serum of patients with chronic renal failure. Clin Chem 1987;33:670-3.
15. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
16. Fraser CG, Williams P. Short-term biological variation of plasma analytes in renal disease. Clin Chem 1983;29:508-10.
17. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
18. Ricós C, Garcia-Lario JV, Alvarez V, Cava F, Domenech M, Hernández A, et al. Biological variation database, and quality specifications for imprecision, bias and total error (desirable and minimum). The 2004 update, http://www.westgard.com/guest26.htm (accessed December 2005).
19. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet 1997;349:1613-7.
20. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005;84:48-60.
21. Nordmann Y, Puy H. Human hereditary hepatic porphyrias. Clin Chim Acta 2002;325:17-37.
22. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias [Review], Ann Intern Med 2005;142:439-50.
23. Iglesias N, Petersen PH, Ricos C. Power function of the reference change value in relation to cut-off points, reference intervals and index of individuality. Clin Chem Lab Med 2005;43:441-8.
24. Iglesias CN, Petersen PH, Jensen E, Ricos C, Jorgensen PE. Reference change values and power functions. Clin Chem Lab Med 2004;42:415-22.
25. Petersen PH, Sandberg S, Fraser CG, Goldschmidt H. Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med 2001;39:160-5.
26. Petersen PH, Fraser CG, Sandberg S, Goldschmidt H. The index of individuality is often a misinterpreted quantity characteristic. Clin Chem Lab Med 1999;37:655-61.